Sectoral Asset Management
VC Fund
Montréal, Canada
Sectoral Asset Management is a VC fund in Montréal focused on Health Care and Biotechnology. Sectoral Asset Management Inc. is an industry-leading specialist in managing global investment portfolios in the healthcare sector. Sectoral maintains offices in Montreal and Geneva and is a proud member of the State Street Global Alliance. They currently manage approximately US $4.0 billion in assets.
- Total investments:
- 64
- Last investment:
- Lead investor:
- 30%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sectoral Asset Management invests in
Stages Sectoral Asset Management invests in
Countries Sectoral Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series B
- $16M–$80M
- Series C
- $39M–$139M
- Post-IPO Equity
- $23M–$230M
Investment Focus
Industry
- Health Care 31 (48%)
- Biotechnology 29 (45%)
- Medical 22 (34%)
- Therapeutics 16 (25%)
- Medical Device 13 (20%)
Stage
- Series B 19 (30%)
- Series C 15 (23%)
- Post-IPO Equity 6 (9%)
- Series D 5 (8%)
- Series A 3 (5%)
Country
- United States 33 (52%)
- United Kingdom 4 (6%)
- France 2 (3%)
- Israel 1 (2%)
- Sweden 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Marc Andre Marcotte
Managing Director & Head of Research
|
Managing Director & Head of Research | Total investments: 9 | Find email | |
Alex Bernal
IT Manager
|
IT Manager | Total investments: 0 | Find email | |
Dimo Vodenitcharov
Network Administrator
|
Network Administrator | Total investments: 0 | Find email | |
Guillaume Aquin
Senior Manager Trading & Operations
|
Senior Manager Trading & Operations | Total investments: 0 | Find email | |
Justin Gelinas
Operations Manager
|
Operations Manager | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation.The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimallyinvasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology. | $90M / Venture - Series Unknown / Sep 22, 2026 | ||
| Sling Therapeutics is a biopharmaceutical company focused on late-stage development for thyroid eye disease, aspiring to improve the lives of patients and their families. | $123M / Series C / Sep 16, 2026 | ||
| Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $50M / Private Equity / Apr 07, 2026 | ||
| SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppressesneural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders. | Series A / Oct 22, 2025 | ||
| Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M / Series C / Aug 20, 2025 | ||
| Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M / Series D / Jul 09, 2025 | ||
| Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $40M / Series E / Mar 10, 2025 | ||
| Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $115M / Series C / Oct 31, 2024 | ||
| LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. | $53.5M / Post-IPO Equity / Mar 21, 2024 | ||
| Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $42M / Series D / Mar 04, 2024 | ||
| See all 64 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sectoral Asset Management invest in?
Sectoral Asset Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 64 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sectoral Asset Management's check size?
Sectoral Asset Management typically joins rounds of $16M–$80M at Series B, $39M–$139M at Series C and $23M–$230M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sectoral Asset Management participates in.
How do I contact Sectoral Asset Management?
Public channels for Sectoral Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sectoral Asset Management?
The team at Sectoral Asset Management includes Marc Andre Marcotte (Managing Director & Head of Research), Alex Bernal (IT Manager) and Dimo Vodenitcharov (Network Administrator), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
